Fundamental Data for ENMD

EntreMed, Inc. is a clinical-stage biopharmaceutical company developing and testing product candidates that address the role of blood and blood vessels in health and disease. They are primarily focused on developing antiangiogenic drugs designed to inhibit the abnormal new blood vessel growth associated with cancer, as well as a broad range of diseasesincluding certain types of blindness and atherosclerosis.

# Employees: 21

Address: 9640 Medical Center Drive,Rockville,MD,USA

Phone: 240 864-2600

Fax: 240 864-2601

Website: www.entremed.com

Email: ginnyd@entremed.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Michael M. Tarnow (Chmn.)

James S. Burns (Presi.; C.E.O.)

Dane R. Saglio (C.F.O.)

Donald S. Brooks (Dir.)

Dwight L. Bush (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 3/11/2010

Mean EPS (Next Qtr): ($0.01)

Mean EPS (Year): ($0.01)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 0

Shares Performance

Period	ENMD	Compare to S&P
YTD	535.80 %	426.20 %
4 Weeks	59.05 %	57.33 %
12 Weeks	98.08 %	86.74 %

Shares Information

Analyst Coverage: N

Avg Volume: 902980

Shares Outstanding: 88M

Market Cap: $0.09B

52 Week High: $1.38

52 Week Low: $0.16

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 ENMD split by factor of 1.050

Earnings Performance

EPS Growth in Last Quarter: 100.00 %

EPS Growth in Last Year: 100.00 %

Sales Growth in Last Quarter: -0.01 %

Sales Growth in Last Quarter: 4.77 %

Financials

Qtr Book Value: ($0.01)

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: -0.010